Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2LALERG
- Development stage
- Phase 4
- Lead developer
- Labo'Life España
- Modality
- Spiegelmers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapy Plasmids → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Protein Replacement mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Natural RNA Aptamers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Unmodified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Long Non-coding RNA (lncRNA) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Peptides, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
**Description:** 2LALERG is a micro-immunotherapy medicine (MIM) developed to decrease chronic IgE-mediated inflammation and symptoms of allergy, particularly in conditions such as allergic rhinitis and allergic respiratory diseases. It is classified as a homeopathic or ultra-low dose (ULD) biological product. The formulation contains ultra-low doses of cytokines, hormones, growth factors, neuropeptides, nucleic acids—including specific nucleic acids (SNAs)—designed to modulate immune responses. Notably, it includes SNA targeting HLA II molecules to control their overexpression and limit IgE secretion; ultra-low dose lung histaminum to inhibit basophil degranulation; and low-dose TGF-β for anti-inflammatory effects via regulatory T cell activation. The mechanism involves selective binding to histamine H1 receptors on target cells—counteracting the effects of histamine released during allergic reactions—and immunomodulation through the above-mentioned components. Preclinical studies have shown that it can reduce inflammatory cell counts and interleukin-13 levels in models of allergic respiratory disease[1][2][5]. Clinical data suggest potential benefit in reducing symptoms when used preventively before pollen season[2].
- Brand names
- 2LALERG
- Other names
- Labolife 2LALERGLabolife2LALERGLabolife-2LALERGmicro-immunotherapy medicine 2LALERGMIM 2LALERGMIM2LALERGMIM-2LALERG
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)MHC II (Major histocompatibility complex class II receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on 2LALERG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2LALERG.